Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.35 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26106950 | 1.00 | SLC22A6 (0.48) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL26107220 | 0.84 | POLB (0.38) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL26107221 | 0.84 | POLB (0.38) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL7378347 | 0.82 | MME (0.44) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL667935 | 0.82 | MME (0.44) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL4748392 | 0.82 | MME (0.44) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL14606193 | 0.81 | SLC22A6 (0.50) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL16600216 | 0.80 | SLC22A6 (0.55) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL14189817 | 0.80 | SLC22A6 (0.55) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL25181478 | 0.78 | SLC22A6 (0.52) | SLC22A6GPR84MAPTGABRR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000783-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | SAPREME TECHNOLOGIES B.V. (NL) | 2026-01-01 | — | — | US | claimed |
| EP-4647436-A2 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | Sapreme Technologies B.V. (NL) | 2025-11-12 | — | — | EP | claimed |
| EP-4635515-A2 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | Sapreme Technologies B.V. (NL) | 2025-10-22 | — | — | EP | claimed |
| EP-3897735-B1 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | SAPREME TECH BV (NL) | 2025-10-22 | — | — | EP | claimed |
| EP-4635501-A2 | SAPONIN DERIVATIVES WITH IMPROVED THERAPEUTIC WINDOW | Sapreme Technologies B.V. (NL) | 2025-10-22 | — | — | EP | claimed |
| EP-4631524-A2 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | Sapreme Technologies B.V. (NL) | 2025-10-15 | — | — | EP | claimed |
| US-20250295800-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | SAPREME TECH BV (NL) | 2025-09-25 | — | — | US | claimed |
| EP-4210761-B1 | SEMICARBAZONE-BASED SAPONIN CONJUGATE | SAPREME TECH BV (NL) | 2025-08-20 | — | — | EP | claimed |
| EP-4596052-A2 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | Sapreme Technologies B.V. (NL) | 2025-08-06 | — | — | EP | claimed |
| EP-4591938-A2 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | Sapreme Technologies B.V. (NL) | 2025-07-30 | — | — | EP | claimed |
| WO-2022055352-A1 | SEMICARBAZONE-BASED SAPONIN CONJUGATE | SAPREME TECHNOLOGIES B.V. (NL) | 2022-03-17 | — | — | WO | claimed |
| EP-3897735-A1 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | SAPREME TECHNOLOGIES B.V. (NL) | 2021-10-27 | — | — | EP | claimed |
| EP-3897741-A1 | IMPROVED CELL-TARGETING BINDING MOLECULE | SAPREME TECHNOLOGIES B.V. (NL) | 2021-10-27 | — | — | EP | claimed |
| EP-3856254-A2 | IMPROVED ANTIBODY-OLIGONUCLEOTIDE CONJUGATE | SAPREME TECHNOLOGIES B.V. (NL) | 2021-08-04 | — | — | EP | claimed |
| EP-3773737-A1 | SAPONIN CONJUGATED TO EPITOPE-BINDING PROTEINS | SAPREME TECHNOLOGIES B.V. (NL) | 2021-02-17 | — | — | EP | claimed |
| WO-2020126620-A2 | IMPROVED ANTIBODY-OLIGONUCLEOTIDE CONJUGATE | SAPREME TECHNOLOGIES B.V. (NL) | 2020-06-25 | — | — | WO | claimed |
| WO-2020126626-A1 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | SAPREME TECHNOLOGIES B.V. (NL) | 2020-06-25 | — | — | WO | claimed |
| WO-2020126064-A1 | SAPONIN CONJUGATED TO EPITOPE-BINDING PROTEINS | SAPREME TECHNOLOGIES B.V. (NL) | 2020-06-25 | — | — | WO | claimed |
| WO-2020126627-A1 | IMPROVED CELL-TARGETING BINDING MOLECULE | SAPREME TECHNOLOGIES B.V. (NL) | 2020-06-25 | — | — | WO | claimed |
| US-20110020226-A1 | PARTICLE STRUCTURES COMPRISING STEROLS AND SAPONINS | NORDIC VACCINE TECHNOLOGY A/S | 2011-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020226-A1 | PARTICLE STRUCTURES COMPRISING STEROLS AND SAPONINS | LSS, SNRPE, HLA-C | SLC22A6 2138/4885GPR84 675/4885MAPT 4825/4885 |
| US-20260000783-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | EPCAM, CD47, FCGR3B | SLC22A6 2453/4885GPR84 1804/4885MAPT 3753/4885 |
| US-20250295800-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | CYP46A1, HCCS, DHCR7 | SLC22A6 1764/4885GPR84 4189/4885MAPT 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.